TBCT Clinical Trial: Study 29: Evaluating Rifapentine Drug in Tuberculosis Treatment

Year: 2008 - 2013


The World Health Organization estimates that there are 175,000 new cases of tuberculosis (TB) in Vietnam every year, 7,000 of which are new multi-drug resistant cases and 6,400 new HIV/TB cases.  Although the Government of Vietnam has made considerable progress in expanding TB services and treatment through its National Tuberculosis Program, the rate of new cases of TB per population has yet to show a significant decline over the last decade (WHO, 2009).

One of the goals of the Tuberculosis Trials Consortium (TBCT) is to conduct research that expands clinical and epidemiologic knowledge of TB and facilitates the diagnosis, clinical management, and prevention of tuberculosis infection and disease. In an effort to contribute to TB control program and in an effort to reduce the duration of TB treatment, TBCT is in the process of implementing Study 29. The purpose of the study is to evaluate the antimicrobial activity and safety of an experimental intensive phase (first 8 weeks of treatment) tuberculosis treatment regimen in which rifapentine is substituted for rifampin.

In conjunction with Westat, ISMS researchers are contributing to Study 29 by monitoring the overall implementation process of study sites in Hanoi.

Read more Link